Medicamen Biotech Enters Strategic Manufacturing & Supply Agreement With US Distributor

Medicamen Biotech Limited has announced a significant partnership under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has entered into a long-term Manufacturing & Supply Agreement with a prominent pharmaceutical distributor and marketing entity operating in the United States and Europe. This strategic collaboration aims to enhance Medicamen Biotech’s global presence and leverage its manufacturing capabilities.

Expansion into International Markets

Under the agreement, Medicamen Biotech will manufacture products for the US-based entity according to its technical specifications. The collaboration is expected to last for ten years, ensuring a stable and long-term engagement. The agreement is strictly a manufacturing and supply arrangement with no share exchange involved. Additionally, 25% of the agreement’s total consideration has been received upon signing.

This partnership aligns with Medicamen Biotech’s growth strategy, reinforcing its position in international markets, particularly in the regulated sectors of the US and Europe. The company’s USFDA-approved oncology unit will play a crucial role in executing this agreement, highlighting its commitment to high-quality manufacturing and research-driven process development.

Leveraging Advanced Manufacturing Capabilities

Medicamen Biotech will utilise its advanced manufacturing infrastructure to produce pharmaceutical products tailored to the requirements of its US partner. The agreement underscores the company’s ability to provide value-added custom manufacturing services, further strengthening its foothold in the global pharmaceutical industry. With no related party transactions involved, this deal has been structured at arm’s length, ensuring transparency and compliance with regulatory norms.

Medicamen Biotech Share Performance

As of February 20, 2025, at 11:33 AM, the shares of Medicamen Biotech are trading at ₹518.00 per share, reflecting a surge of 4.27% from the previous day’s closing price.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.